The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook. Each has run hard off 2025 lows, and the fundamentals no longer line up the same way.
Johnson & Johnson: The Rerating Has Legs
J&J has posted four straight EPS beats and accelerating revenue growth, from +5.8% in Q2 2025 to +9.9% in Q1 2026. Management raised 2026 guidance to $100.3B–$101.3B in sales and $11.45–$11.65 in adjusted EPS. DARZALEX at $3.96B (+22.5%) and TREMFYA at $1.61B (+68.3%) are more than absorbing the STELARA biosimilar cliff.
The setup: shares are up 20.69% year to date and 63.17% over one year, yet the stock trades at a forward P/E of 22, backed by a 2.02% dividend yield and 64 consecutive years of hikes.
Analysts carry a $262.27 consensus target against the current $247.02, with 15 Buy, 7 Hold, 1 Sell. Targets are not guarantees, but the Orthopaedics separation and Enterprise Business Review on December 8, 2026 are near-term catalysts. Litigation charges of $330M in Q1 remain the swing factor to watch.
Eli Lilly: Great Company, Priced for Perfection
Lilly’s Q1 2026 revenue jumped 55.5% to $19.80B with adjusted EPS of $8.55 beating $6.79 estimates by 25.88%. Mounjaro hit $8.66B (+125%) and Zepbound reached $4.16B (+80%). Guidance was lifted to $82B–$85B revenue and $35.5–$37 EPS, and the Foundayo oral GLP-1 approval opens a larger addressable pool.
The challenge is price. Shares have already climbed 50.92% over one year and 421.48% over five, and the stock trades at a trailing P/E of 42 and forward P/E of 33.
Realized prices fell 13% in Q1, Mounjaro and Zepbound together account for 64.7% of revenue, and prediction-market sentiment has slipped 21.4 points over 30 days. With 23 Buy, 5 Hold, 2 Sell and a $1,254.07 target implying modest upside, the risk/reward argues for patience until pricing and competition stabilize.
AbbVie: The Multiple Has Detached From the Math
Skyrizi at $4.48B (+30.9%) and Rinvoq at $2.12B (+23.3%) are outrunning Humira erosion (Humira at $688M, down 38.6%), and 2026 EPS guidance was nudged to $14.08–$14.28. That is a real business. The valuation is the sticking point.
ABBV trades at a trailing P/E of 122 and price-to-book of 50, on negative book value of -$3.77, after rising 35.04% over one year and 481.43% over ten.
Q1 adjusted EPS of $2.65 missed by 0.66%, weighed by $744M in IPR&D charges on top of $5B for full-year 2025. Analysts still model a $265.50 target with 24 Buy, 6 Hold, 1 Sell, but one predictive model implies -30.9% downside to $168.67. With growth concerns building beyond 2028 and Imbruvica down 24.7%, the risk/reward has narrowed.
The bottom line
All three stocks have outrun the S&P 500’s mid-single-digit gain year to date. J&J’s rerating still has room on the fundamentals, Lilly’s setup argues for patience after a strong run, and AbbVie’s multiple looks demanding relative to the growth math. This is analysis, not investment advice — investors should weigh their own objectives and risk tolerance.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks